Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: A review of the national cancer data base

Journal of Clinical Oncology

Volumn 33, Issue 8, 2015, Pages 870-876

  Robinson, Cliff G ^a   Patel, Aalok P ^a   Bradley, Jeffrey D ^a   DeWees, Todd ^a   Waqar, Saiama N ^a   Morgensztern, Daniel ^a   Baggstrom, Maria Q ^a   Govindan, Ramaswamy ^a   Bell, Jennifer M ^a   Guthrie, Tracey J ^a   Colditz, Graham A ^a   Crabtree, Traves D ^a   Kreisel, Daniel ^a   Krupnick, Alexander S ^a   Patterson, G Alexander ^a   Meyers, Bryan F ^a   Puri, Varun ^a  

^a 4921 Parkview Place ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHARLSON COMORBIDITY INDEX; CONTROLLED STUDY; DATA BASE; FEMALE; FOLLOW UP; GENDER; HEALTH CARE FACILITY; HUMAN; INCOME; LOBECTOMY; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; TUMOR VOLUME; UNIVARIATE ANALYSIS; URBAN POPULATION; ADJUVANT CHEMOTHERAPY; CANCER REGISTRY; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; FACTUAL DATABASE; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; SEER PROGRAM; TREATMENT OUTCOME; UNITED STATES; URBAN POPULATION;

EID: 84924862191     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.5380     Document Type: Article

References (26)

1. Siegel R, Ma J, Zou Z, et al: Cancer statistics, 2014. CA Cancer J Clin 64:9-29, 2014
2. Ferlay J, Shin HR, Bray F, et al: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917, 2010
3. Detterbeck FC, Boffa DJ, Tanoue LT: The new lung cancer staging system. Chest 136:260-271, 2009
4. NSCLC Meta-analyses Collaborative Group, Arriagada R, Auperin A, et al: Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: Two metaanalyses of individual patient data. Lancet 375:1267-1277, 2010
5. Le Péchoux C: Role of postoperative radiotherapy in resected non-small cell lung cancer: A reassessment based on new data. Oncologist 16: 672-681, 2011
6. PORT Meta-analysis Trialists Group: Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev 2:CD002142, 2005
7. Douillard JY, Rosell R, De Lena M, et al: Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: The Adjuvant Navelbine International Trialist Association (ANITA) randomized trial. Int J Radiat Oncol Biol Phys 72:695-701, 2008
8. Lally BE, Detterbeck FC, Geiger AM, et al: The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: Analysis of the Surveillance, Epidemiology, and End Results database. Cancer 110:911-917, 2007
9. Lally BE, Zelterman D, Colasanto JM, et al: Postoperative radiotherapy for stage II or III nonsmall- cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 24:2998-3006, 2006
10. Newman LA, Lee CT, Parekh LP, et al: Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients: A report from the American College of Surgeons Oncology Group (ACOSOG) Special Population Committee. Cancer 106:188-195, 2006
11. Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613-619, 1992
12. Cole SR, Hernán MA: Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed 75:45-49, 2004
13. Billiet C, Decaluwé H, Peeters S, et al: Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: A meta-analysis. Radiother Oncol 110:3-8, 2014
14. Miles EF, Kelsey CR, Kirkpatrick JP, et al: Estimating the magnitude and field-size dependence of radiotherapy-induced mortality and tumor control after postoperative radiotherapy for nonsmall- cell lung cancer: Calculations from clinical trials. Int J Radiat Oncol Biol Phys 68:1047-1052, 2007
15. Phlips P, Rocmans P, Vanderhoeft P, et al: Postoperative radiotherapy after pneumonectomy: Impact of modern treatment facilities. Int J Radiat Oncol Biol Phys 27:525-529, 1993
16. Machtay M, Lee JH, Shrager JB, et al: Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma. J Clin Oncol 19:3912-3917, 2001
17. Dautzenberg B, Arriagada R, Chammard AB, et al: A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma: Groupe d'Etude et de Traitement des Cancers Bronchiques. Cancer 86:265-273, 1999
18. Bradley JD, Paulus R, Graham MV, et al: Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA nonsmall- cell lung cancer: Promising long-term results of the Radiation Therapy Oncology Group-RTOG 9705. J Clin Oncol 23:3480-3487, 2005
19. Le Pechoux C: Radiation therapy in treating patients with non small cell lung cancer that has been completely removed by surgery (LUNG ART). https://clinicaltrials.gov/ct2/show/NCT00410683
20. Lilenbaum RC, Herndon JE 2nd, List MA, et al: Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The Cancer and Leukemia Group B (study 9730). J Clin Oncol 23:190-196, 2005
21. Zukin M, Barrios CH, Pereira JR, et al: Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol 31:2849-2853, 2013
22. Simon GR, Manegold C, Barker SS, et al: Pemetrexed use in the adjuvant setting for completely resectable non-small-cell lung cancer. Clin Lung Cancer 14:601-608, 2013
23. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
24. Chansky K, Sculier JP, Crowley JJ, et al: The International Association for the Study of Lung Cancer Staging Project: Prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 4:792-801, 2009
25. Firat S, Byhardt RW, Gore E: Comorbidity and Karnofsky performance score are independent prognostic factors in stage III non-small-cell lung cancer: An institutional analysis of patients treated on four RTOG studies. Int J Radiat Oncol Biol Phys 54:357-364, 2002
26. Ginsberg RJ, Rubinstein LV: Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer: Lung Cancer Study Group. Ann Thorac Surg 60:615-622, 1995